TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32954238
Drug: Smartphone application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application UnityPhilly for naloxone administration
Study: 32954622
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients (combined treatment)
Study: 32958482
Drug: Post-treatment IgM
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment IgM concentrations
Study: 32958628
Drug: Hybrid Closed-Loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid Closed-Loop Insulin Therapy
Study: 32958709
Drug: 140-mg loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140-mg loading dose of caspofungin (CAS)
Study: 32959922
Drug: H. perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. perforatum extract (after 2 weeks treatment)
Study: 32959922
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline measurements before H. perforatum treatment)
Study: 32963347
Drug: buparlisib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: buparlisib monotherapy
Study: 32963347
Drug: buparlisib and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: buparlisib and cetuximab combination
Study: 32964020
Drug: Trandolapril/Verapamil fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril/Verapamil fixed-dose combination
Study: 35445317
Drug: Passeo-18 Lux
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Passeo-18 Lux drug-coated balloon (DCB)
Study: 32965548
Drug: Iberdomide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide (0.6 mg) alone
Study: 32965548
Drug: Iberdomide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide (0.6 mg) with itraconazole (200 mg twice daily on day 1 and 200 mg once daily on days 2 through 9)
Study: 32965548
Drug: Iberdomide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide (0.6 mg) with rifampin (600 mg QD days 1 through 13)
Study: 32965659
Drug: Ivacaftor 150
Normalized name: ivacaftor 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivacaftor 150 mg orally every 12 hours for 104 weeks
Study: 32967009
Drug: CART2 (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: CART2 (second infusion of CD19 CAR T cells)
Study: 32967807
Drug: Daratumumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab monotherapy (16 mg/kg, intravenously weekly for 8 weeks, biweekly for 16 weeks, and every 4 weeks thereafter)
Study: 32968710
Drug: Intravenous Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous Golimumab (GLM-IV)
Study: 32969724
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) 5 mg/kg/d
Study: 32971036
Drug: Obinutuzumab plus
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab plus DHAP (dexamethasone, high-dose cytarabine, and cisplatin)
Study: 32971187
Drug: Olaparib 50
Normalized name: olaparib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 50 mg twice a day
Study: 32971187
Drug: Olaparib 100
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 100 mg twice a day
Study: 32971187
Drug: Olaparib 150
Normalized name: olaparib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 150 mg twice a day
Study: 32971187
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg twice a day
Study: 32972204
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose during CTO-PCI
Study: 32972320
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of antiphospholipid antibodies (mainly lupus anticoagulant)
Study: 32974150
Drug: Radical Intensity-Modulated
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical Intensity-Modulated Radiation Therapy
Study: 32974208
Drug: Moderately hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately hypofractionated intensity modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) and pelvic lymph node coverage.
Study: 32975711
Drug: Early combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combination therapy with two glucose-lowering drugs
Study: 32975711
Drug: Stepwise approach
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise approach starting with metformin
Study: 32975869
Drug: Isatuximab 20
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab 20 mg/kg QW/Q2W
Study: 32976514
Drug: Semi-annual MDA
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-annual MDA (ivermectin 0.2 mg/kg + albendazole 400 mg)
Study: 32976514
Drug: Annual MDA
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual MDA (ivermectin 0.2 mg/kg + albendazole 400 mg)
Study: 32977309
Drug: 124I-8H9 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 124I-8H9 monoclonal antibody (124I-omburtamab) administered by CED
Study: 32977309
Drug: Second infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second infusion of 124I-8H9 monoclonal antibody (124I-omburtamab)
Study: 32977309
Drug: First and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First and second infusions of 124I-8H9 monoclonal antibody (124I-omburtamab)
Study: 32977351
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or conventional treatment (including blood transfusion and hydroxyurea)
Study: 32978101
Drug: Tyrosine and
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine and serine/threonine kinase inhibitors (TKIs)
Study: 32978101
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of at least three concomitant medications
Study: 32979106
Drug: Docetaxel (D)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (D) 75 mg/m²
Study: 32979106
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of docetaxel and pegylated liposomal doxorubicin
Study: 32979560
Drug: Adjunctive brexpiprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brexpiprazole 2-3 mg/day for 8 weeks
Study: 32979984
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with intravenous paclitaxel (200 mg/m2) and nivolumab
Study: 32979984
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with intravenous paclitaxel and nivolumab
Study: 32980364
Drug: Control (recent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (recent ACE inhibitor/ARB initiation/dose change)
Study: 32980834
Drug: ω-3 fatty
Normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 fatty acids and low-dose aspirin as adjuncts to periodontal debridement
Study: 32982210
Drug: Enjoying Breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enjoying Breathing Program intervention including online and face-to-face courses for health care providers, standard therapy, self-management education, rehabilitation exercises, and follow-up every 3 months.
Study: 32982387
Drug: Post-operative morphine
Normalized name: Sx1 Medicated Post-Operative System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative morphine
Study: 32982933
Drug: Purified Anthocyanins,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Anthocyanins, dosage and duration not available
Study: 32982944
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose of Atorvastatin
Study: 32982950
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of Virtual Reality and Transcranial Direct Current Stimulation
Study: 32983991
Drug: S-1-based chemoradiotherapy
Normalized name: menthol 1 MG [Luden's]
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1-based chemoradiotherapy followed by consolidation chemotherapy with S-1
Study: 32984371
Drug: Non-invasive drug
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive drug monitoring of β-Lactam antibiotics using sweat analysis
Study: 32987824
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance tests (OGTT) with doses of 25 g, 75 g, and 125 g
Study: 32987824
Drug: Isoglycaemic intravenous
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoglycaemic intravenous (i.v.) glucose infusions (IIGI)
Study: 32988829
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (10 mg/kg of body weight/6 h)
Study: 32988829
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and oral acyclovir
Study: 32988948
Drug: Oral steroids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids, intratympanic steroid injections, or a combination of both (exact dosages and durations not specified)
Study: 32989226
Drug: ODM-207 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM-207 (2 mg/kg)
Study: 32989552
Drug: JTX-4014 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTX-4014 (500 mg every 3 weeks or 1000 mg every 6 weeks)
Study: 32989776
Drug: First-line tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line tyrosine kinase inhibitors (TKIs)
Study: 32989856
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma treatment
Study: 32990181
Drug: Carcinogenic HPVs
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carcinogenic HPVs in nonavalent vaccine (HPV16,18,31,33,45,52,58)
Study: 32990324
Drug: Mepolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (300 mg; three separate injections every four weeks for 52 weeks)
Study: 38393328
Drug: Mepolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (300 mg)
Study: 32990324
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg twice a week) or Belimumab (10 mg/kg on days 0, 14, 28 and every 28 days thereafter until 12 months after the last participant was randomised) with standard therapy
Study: 32990324
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg twice a week)
Study: 32990629
Drug: Video directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video directly observed therapy (VDOT) with smartphone app, weekly internet subscription, translated text message reminders, and incentives for adherence
Study: 32990629
Drug: Usual-care directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-care directly observed therapy (DOT)
Study: 32990938
Drug: Extended-release dinalbuphine
Normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release dinalbuphine sebacate (ERDS)
Study: 32990945
Drug: Pine bark
Normalized name: pine bark extract
DrugBank: Maritime pine extract (DB15786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pine bark extract supplements
Study: 32991329
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to multiple SARS-CoV-2 antigens
Study: 32991329
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to HCoV-OC43 and HCoV-HKU1 spike S2
Study: 32992048
Drug: Angiotensin-converting-enzyme inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting-enzyme inhibitors (ACEI)
Study: 32992048
Drug: Angiotensin-receptor blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-receptor blockers (ARB)
Study: 32992341
Drug: Pembrolizumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab monotherapy (3 cycles) followed by AVD chemotherapy (4 to 6 cycles)
Study: 32992341
Drug: AVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVD chemotherapy (after pembrolizumab)
Study: 32992341
Drug: Pembrolizumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab monotherapy followed by AVD
Study: 32993275
Drug: BPH screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPH screening tool (score ≥3) and serum PSA ≥2 ng/mL
Study: 32993275
Drug: IPSS ≥8
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPSS ≥8 and serum PSA ≥2 ng/mL
Study: 32993521
Drug: CRP cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP cut-off of 3 mg/l
Study: 32993559
Drug: PZQ treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ treatment immediately after diagnosis
Study: 32993559
Drug: PZQ treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZQ treatment after delivery
Study: 32993772
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Alzheimer's biomarkers (t-Tau, P-Tau, Aβ42, Aβ40)
Study: 32993794
Drug: BEZ235 (300-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 (300-400 mg BID)
Study: 32993794
Drug: BEZ235 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 (300 mg BID)
Study: 32995919
Drug: Standard IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IV intermittent bolus paracetamol therapy (15-mg/kg doses as 1-h infusions every 6 h for 5 days)
Study: 32995919
Drug: Continuous IV
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV paracetamol infusion therapy (60-mg/kg/day continuously for 5 days)
Study: 32995944
Drug: Pridopidine 1
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 1 mg
Study: 32995944
Drug: Pridopidine doses
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine doses ranging from 22.5 to 90 mg
Study: 32996064
Drug: Ceftolozane/tazobactam 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane/tazobactam 3 g (ceftolozane 2 g/tazobactam 1 g)
Study: 32996064
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g
Study: 32996096
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI) 80 U subcutaneously every other day to week 4, then twice weekly to week 24
Study: 32998963
Drug: Itacitinib (INCB039110),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib (INCB039110), a JAK1 inhibitor
Study: 32998965
Drug: Alvocidib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvocidib (30 mg/m²) followed by 7+3 (Cytarabine 100 mg/m² + Daunorubicin)
Study: 32998965
Drug: Alvocidib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvocidib (30 mg/m²)
Study: 33000661
Drug: Crystalloid administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystalloid administration within the preceding 24 hours
Study: 33001549
Drug: Bilateral dorsolateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral dorsolateral prefrontal cortex (DLPFC) theta burst stimulation (TBS) treatment for 2 weeks
Study: 33001967
Drug: SARS-CoV-2 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 antibodies (detected via lateral flow immunoassay test)
Study: 33002543
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg) and Nivolumab (1 mg/kg) every 3 weeks for 4 doses followed by Nivolumab monotherapy (480 mg) every 4 weeks until progression or up to 1 year after consolidative thoracic radiation therapy (30 Gy in 10 fractions).
Study: 33002543
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg) and Nivolumab (1 mg/kg) with thoracic radiation therapy after platinum chemotherapy.
Study: 33002543
Drug: Ipilimumab and
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab and Nivolumab treatment.
Study: 33002543
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in peripheral blood CD3+CD8+ from baseline to after first dose of IPI/NIVO.
Study: 33003016
Drug: Vasopressor dose
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressor dose
Study: 33004046
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion radiotherapy (CIRT) with a total irradiation dose of 48 Gy (RBE) delivered in twelve fractions; concurrent chemotherapy accepted if indicated.
Study: 33004541
Drug: Chemotherapy/ICI combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy/ICI combinations
Study: 33004542
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg intravenous every 3 weeks + Bevacizumab 15 mg/kg intravenous every 3 weeks
Study: 33004656
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic volume of 5 mL
Study: 33004656
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic volume of 30-35 mL
Study: 33004656
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic volume (various doses from 5 to 40 mL)
Study: 33004691
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IGF1 treatment
Study: 33007932
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment strategies according to local protocols in cardiac centers
Study: 33007932
Drug: Invasive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive therapy and antithrombotic therapy including patient-tailored strategies
Study: 33008303
Drug: Chronic kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic kidney disease (CKD) defined as GFR < 60, < 45 or < 30 ml/min/1.73 m²
Study: 33008303
Drug: Chronic kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic kidney disease (CKD) defined as eGFR < 45 or 30 ml/min/1.73 m²
Study: 33008401
Drug: New estrogen-free
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: New estrogen-free contraceptive pill (4 mg drospirenone, 24/4 regimen)
Study: 33008435
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy for challenging behavior
Study: 33008435
Drug: Non-medication approaches
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-medication approaches
Study: 33008938
Drug: Breath volatile
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath volatile organic compounds
Study: 33010149
Drug: HCV direct-acting
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV direct-acting antiviral treatment
Study: 33010149
Drug: HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV treatment scale-up
Study: 33010231
Drug: ARI-0001 cells
Normalized name: OVIS ARIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARI-0001 cells (chimeric antigen receptor T cells targeting CD19)
Study: 33010459
Drug: Tivozanib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib 1.5 mg QD plus nivolumab 240 mg every 2 weeks
Study: 33010459
Drug: Tivozanib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib 1.5 mg QD
Study: 33010817
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin at 1.8 mg/kg (cap at 180 mg) and nivolumab at 3 mg/kg, both intravenously every 21 days for 8 cycles
Study: 33010927
Drug: Intramuscular tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular tranexamic acid (TXA) 1 g i.v. loading dose followed by two 5 ml (0.5 g each) i.m. injections
Study: 33010927
Drug: Intramuscular tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular tranexamic acid (TXA)
Study: 33011782
Drug: Chemotherapy-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-only treatment (phase 3 trial)
Study: 33011923
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100 units/mL, given once daily after switching from other basal insulins
Study: 33012343
Drug: Cell therapy
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell therapy (CD34)
Study: 33012782
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg Q2W) + Gefitinib (250 mg QD)